ProQR Therapeutics N.V. is a biotechnology company that specializes in the development and discovery of novel therapeutic medicines. The company boasts an impressive pipeline of products, including AX-0810 for cholestatic diseases, which targets Na-taurocholate cotransporting polypeptide (NTCP), as well as AX-1412 for cardiovascular diseases (CVDs), which targets Beta-1,4-galactosyltransferase 1 (B4GALT1). ProQR Therapeutics N.V. is also developing various other early-stage research programs, such as AX-1005, AX-2911, AX-0601, AX-9115, and AX-2402. Additionally, the company is developing the Axiomer RNA base-editing platform technology. ProQR Therapeutics N.V. has established notable partnerships with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., Leiden University Medical Center, and Eli Lilly and Company. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.